{"name":"AryoGen Pharmed Co.","slug":"aryogen-pharmed-co","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Novoseven","genericName":"Novoseven","slug":"novoseven","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Bevacizumab + FOLFIRI-3","genericName":"Bevacizumab + FOLFIRI-3","slug":"bevacizumab-folfiri-3","indication":"Metastatic colorectal cancer (Phase 3 pipeline indication)","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Eptacog alfa, biosimilar","genericName":"Eptacog alfa, biosimilar","slug":"eptacog-alfa-biosimilar","indication":"Hemophilia A or B with inhibitors","status":"phase_3"}]}],"pipeline":[{"name":"Novoseven","genericName":"Novoseven","slug":"novoseven","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Bevacizumab + FOLFIRI-3","genericName":"Bevacizumab + FOLFIRI-3","slug":"bevacizumab-folfiri-3","phase":"phase_3","mechanism":"Bevacizumab blocks VEGF to inhibit tumor angiogenesis, while FOLFIRI-3 (fluorouracil, leucovorin, and irinotecan) provides chemotherapy-induced DNA damage and cell death.","indications":["Metastatic colorectal cancer (Phase 3 pipeline indication)"],"catalyst":""},{"name":"Eptacog alfa, biosimilar","genericName":"Eptacog alfa, biosimilar","slug":"eptacog-alfa-biosimilar","phase":"phase_3","mechanism":"Eptacog alfa is a recombinant activated Factor VII that bypasses upstream coagulation defects to directly activate Factor X and initiate thrombin generation for hemostasis.","indications":["Hemophilia A or B with inhibitors","Factor VII deficiency","Glanzmann thrombasthenia with refractoriness to platelet transfusion"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNVVo5UTZGRHBtb243eW5ETlhtRmF6bi01N29md2NEYXRHZFdPTVdxX0dqanNzR3NDMGM1dmFyeEZqNWFCRGRyWDVsRU1pd0R1N3dxNHdNd0VnVENvamQ1dzByMlgtNTlidlZSTXBPTkM2Z0VwWTV0SHplOGRNbFBrb2lycHRaeUtqN3htTkVvVVN5MDA0bFRNSDJ1Z01HanpLY282WnZ4WDdSOGVVT0xBNUFlNFhZb1BWcHctN2lMelhmRDVKWU5SUjNmdW5KcmZxV3hNVHpQaGlidmdLMllLc21KUQ?oc=5","date":"2026-03-03","type":"pipeline","source":"Bangkok Post","summary":"Government Pharmaceutical Organisation confirms medicine stocks sufficient amid Mideast tensions - Bangkok Post","headline":"Government Pharmaceutical Organisation confirms medicine stocks sufficient amid Mideast tensions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQ2g4dkNMdng4NGZ2d1RONFlSckN2aXRIbGFENEFJa0s0RnZLSUxtZ2h6WUNCd0ROUDZpeDd6eUluYTNZNUJvY0l1WFFvWU8yZzlmR1hMMkhIdi1YZVYwVUdveGtWVjRxa1QteDBvTVJoMEZraEp5ZlRycjJCZ1o4NVFOZ0ZLNm5kV2hoYS1qb1Y2ZDNyQ1ljZEZjN0tJREhHbjBOZ2xqLU4?oc=5","date":"2025-10-20","type":"pipeline","source":"Forbes Middle East","summary":"Haleh Hamedifar - Forbes Middle East","headline":"Haleh Hamedifar","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-15","type":"patent","source":"Новости GxP","summary":"The Ministry of Health has registered the first Russian biosimilar of denosumab for the treatment of osteoporosis - Новости GxP","headline":"The Ministry of Health has registered the first Russian biosimilar of denosumab for the treatment of osteoporosis - Ново","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQX1BrelRXQVBNbFdPY0k3NDY3M3ZDLVN0clFlWVlQeFV3bC1RR3pWei1kZnJzQkJtcF95NlpaTk41Q1R2eFN5VzVmczVQRUlxYXdPOHV0NS1Ec2VEdHhETjJiS3ltX1BHVGp4aVRnbEhvdkowMWxaX0R5cWpNWEF5WnJ3?oc=5","date":"2024-03-06","type":"regulatory","source":"pharmaphorum","summary":"Sandoz gets first FDA OK for denosumab biosimilars - pharmaphorum","headline":"Sandoz gets first FDA OK for denosumab biosimilars","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOUUhzUW04STZQSjV5aFJUcGtnRkR1bm9MNlE4bHh2RzA4bm54SW1iTTJBaUgzVjJYRXk0UXROWWNkSUVTeHJ0SnpJNS1PVVZFS1BEd05Hd19wbGRISWw2b193WTVPZnN1ZVRsNVZ5QldFamFTaU1zOXVvWWV2TFJwZ0d0YkpGTTQ?oc=5","date":"2023-02-07","type":"patent","source":"pharmaphorum","summary":"Sandoz files biosimilar of Amgen osteoporosis drug in US - pharmaphorum","headline":"Sandoz files biosimilar of Amgen osteoporosis drug in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1MRXU2aFJBejdrZEZjdmdHaTNOenVnZUFoREtBNGFuOUg3LURCWTJlbjB0dXc2SlptdDVsUDFGc2JyMUFMOF9LdkVnY0tNTnVNOFFyZkwwZHpyMmVFTFhuMi10R1RvdjI3bjJBczhLbzlqY0ZuUndMVUp5dw?oc=5","date":"2021-06-30","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Biosimilars of denosumab - Generics and Biosimilars Initiative","headline":"Biosimilars of denosumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOczd4SEwyQVdrQ0dsOF9BQ2NiV01YSUJXUEozY1VkOTlBNUJ4SlpwZHI2Z0RINWsyNldvQWlGNENmTHFQV0hwQjY2Z3duckxkcEk0RUZlbkZlY3JQeEpPVHFwcXQzODlCXzdORkJ0UkZCYTlYaDlrdkRTRzVaUGhnd201cVBBZlpyaUhQSWRmclM2SXVlUjVMY1ZWV3JFZmw2UlHSAa8BQVVfeXFMTTlwdDZYdVJWRzdZRmpsaGpRYjRfOXNZc0h6MW9FZVZCSmdHX3B1clVYdEhPNWotejZRUnkyM0k4Ql9SYjFHdk9xTkZVMzFnUl9EV3AtdUtRM1N2X2Q4YktycnJuYUFNMjFXQnh6VEFrck5tVW40bk9obGk0Y0lWc3Y4TlNBUlNNQUZEZGR4S3BsS19BQTRDeHpvV1BWOXhGbUgxa2Y1RDZrSlZiTWVPVQ?oc=5","date":"2021-06-02","type":"pipeline","source":"SunStar Publishing Inc.","summary":"Biocare launches 'Temziva' to defeat Covid-19 - SunStar Publishing Inc.","headline":"Biocare launches 'Temziva' to defeat Covid-19","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}